A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
第2相
完了
NCT05596734
| 対象疾患 | Influenza, Human, COVID-19 |
|---|
| 相 | 第2相 |
|---|
| スポンサー | BioNTech SE |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 1,019 名 |
|---|
| 介入（薬剤） | bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV |
|---|
| 開始日 | 2022年10月28日 |
|---|
| 完了日 | 2023年12月28日 |
|---|
| 結果公開日 | 2025年7月23日 |
|---|
概要
Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). Participants will receive either: * qIRV (22/23)/bivalent BNT162b2 (original/Omi BA.4/BA.5), at 1 of the 3 dose-level combinations * qIRV (22/23) at dose level 1, * qIRV (22/23) at dose level 2, or * bivalent BNT162b2 (original/Omi BA.4/BA.5) at dose level 1 administered concurrently in the opposite arm to commercially licensed quadrivalent influenza vaccine (QIV). Substudy B: This Phase 1/2 study will describe the safety, tolerability, and immunogenicity of quadrivalent influenza vaccine (qIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), trivalent influenza vaccine (tIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), and bivalent influenza vaccine (bIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5) when given concurrently with licensed quadrivalent influenza vaccine (QIV).
SSA: Percentage of Participants With Local Reactions up to 7 Days Following Vaccination (18-64 Years)
SSA: From Day 1 to Day 7 after Vaccination · Percentage of participants
| Substudy A, 18-64 Years: qIRV /Bivalent BNT162b2 (90 mcg Combination 1) | 83.3 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV /Bivalent BNT162b2 60 mcg | 89.3 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV /Bivalent BNT162b2 (90 mcg Combination 2) | 80.0 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV 30 mcg | 63.3 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV 60 mcg | 73.3 Percentage of participants |
|---|
| Substudy A, 18-64 Years: Bivalent BNT162b2 (30 mcg) /QIV | 71.9 Percentage of participants |
|---|
SSA: Percentage of Participants With Local Reactions up to 7 Days Following Vaccination (>=65 Years)
SSA: From Day 1 to Day 7 after Vaccination · Percentage of participants
| Substudy A, >=65 Years: qIRV /Bivalent BNT162b2 (90 mcg Combination 1) | 84.8 Percentage of participants |
|---|
| Substudy A, >=65 Years: qIRV /Bivalent BNT162b2 60 mcg | 53.1 Percentage of participants |
|---|
| Substudy A, >=65 Years: qIRV /Bivalent BNT162b2 (90 mcg Combination 2) | 84.8 Percentage of participants |
|---|
| Substudy A, >=65 Years: qIRV 30 mcg | 63.6 Percentage of participants |
|---|
| Substudy A, >=65 Years: qIRV 60 mcg | 72.7 Percentage of participants |
|---|
| Substudy A, >=65 Years: Bivalent BNT162b2 (30 mcg) /QIV | 51.5 Percentage of participants |
|---|
SSA: Percentage of Participants With Systemic Events up to 7 Days Following Vaccination (18-64 Years)
SSA: From Day 1 to Day 7 after Vaccination · Percentage of participants
| Substudy A, 18-64 Years: qIRV /Bivalent BNT162b2 (90 mcg Combination 1) | 76.7 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV /Bivalent BNT162b2 60 mcg | 78.6 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV /Bivalent BNT162b2 (90 mcg Combination 2) | 70.0 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV 30 mcg | 53.3 Percentage of participants |
|---|
| Substudy A, 18-64 Years: qIRV 60 mcg | 63.3 Percentage of participants |
|---|
| Substudy A, 18-64 Years: Bivalent BNT162b2 (30 mcg) /QIV | 68.8 Percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。